Summary:
- The article examines the historical limitations of CAR-T cell therapy, specifically noting its efficacy in B-cell malignancies while highlighting the persistent challenges in treating T-cell leukemia.
- It discusses the biological hurdles to T-cell-directed CAR-T therapies, such as "fratricide" (where CAR-T cells kill each other) and the risk of contaminating the final cell product with malignant T-cells during manufacturing.
- The piece explores emerging scientific strategies to overcome these obstacles, including gene-editing techniques (such as CRISPR/Cas9) to knock out target antigens on the therapeutic cells and the development of "off-the-shelf" allogeneic approaches.